Proposed by Academician Zheng Shusen’s team in 2008, the Hangzhou criteria first introduced tumor biology and pathology characteristics as selection criteria for liver transplant recipients, marking a breakthrough from previous criteria limited to tumor morphology.[33] However, the Hangzhou criteria are based on AFP, mainly applied to HCC and having little clinical significance for ICC. The gene discussed is AFP; the disease is intrahepatic cholangiocarcinoma.